A new vaccine that protects against Covid-19 is nearly 95% effective, early data from US company Moderna shows.
The results come hot on the heels of similar results from Pfizer, and add to growing confidence that vaccines can help end the pandemic.
Both companies used a highly innovative and experimental approach to designing their vaccines. Moderna says it is a “great day” and they plan to apply for approval to use the vaccine in the next few weeks.
The trial involved 30,000 people in the US with half being given two doses of the vaccine, four weeks apart. The rest had dummy injections.The analysis was based on the first 95 to develop Covid-19 symptoms.
Only five of the Covid cases were in people given the vaccine, 90 were in those given the dummy treatment. The company says the vaccine is protecting 94.5%. The data also shows there were 11 cases of severe Covid in the trial, but none happened in people who were immunised.
Moderna says it will apply to regulators in the US in the coming weeks. It expects to have 20 million doses available in the country.
The company hopes to have up to one billion doses available for use around the world next year and is planning to seek approval in other countries too